Study design: Allocation: Randomized Endpoint classification: Efficacy study Masking: Open label Primary purpose: Treatment Primary endpoint: Incidence of reaching the target serum trough concentration Secondary endpoint: Clinical efficiency, Antibiotic use, acute kidney injury.
This is a prospective randomized control trial. There are two groups, study group and control group. Patients of study group accepted vancomycin strategies decided by a serum trough concentration model, and patients of control group accepted vancomycin dosage decided by attending physician. The primary endpoint is the incidence of reaching the target serum trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side effects such as acute kidney injury, etc.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
66
Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
Peking University Third Hospita
Beijing, Beijing Municipality, China
The incidence of vancomycin therapeutic serum trough concentrations
The proportion of patients with vancomycin serum trough concentrations reaching target concentrations (≥15mg/L)will be compared between study group and control group
Time frame: before the fifth vancomycin dosage
Clinical success rate
the proportion of patients with clinical success
Time frame: Seven days after vancomycin withdrawal.
Vancomycin doses
Vancomycin daily doses and totally doses
Time frame: At the end of vancomycin therapy, an average of 10 days.
Incidence of acute kidney injury
The incidence of vancomycin-associated acute kidney injury
Time frame: At the end of vancomycin treatment, an average of 10 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.